Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 2pasireotide 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1abemaciclib 1Temozolomide 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Oxaliplatin 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1Everolimus 1E-7386 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastro-enteropancreatic neuroendocrine tumor × Octreotide × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡